Studies of catecholamine metabolism in schizophrenia/psychosis--II. 1993

J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
Department of Psychiatry, University of Texas Health Science Center, San Antonio 78284-7792.

Acutely psychotic schizophrenic patients were maintained on debrisoquin (DBQ) throughout 5 weeks of treatment with haloperidol. Treatment with haloperidol caused initial increases in urinary homovanillic acid (HVA) output that returned toward baseline by the 5th week. During haloperidol treatment, plasma levels of HVA tended to decrease, concurrent with increased renal clearance of HVA. Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels and urinary MHPG output both decreased over the course of treatment. The differences in HVA and MHPG metabolism suggest differential effects of treatment on dopamine and norepinephrine systems. Neuroleptic treatment also abolished the marked morning decreases in plasma HVA concentrations (reported in part I).

UI MeSH Term Description Entries
D008297 Male Males
D008734 Methoxyhydroxyphenylglycol Synthesized from endogenous epinephrine and norepinephrine in vivo. It is found in brain, blood, CSF, and urine, where its concentrations are used to measure catecholamine turnover. Hydroxymethoxyphenylglycol,MHPG,MOPEG,Vanylglycol,4-Hydroxy-3-methoxyphenylethylene Glycol,4-Hydroxy-3-methoxyphenylethyleneglycol,4-Hydroxy-3-methoxyphenylglycol,Methoxyhydroxyphenylglycol, (+)-Isomer,Methoxyhydroxyphenylglycol, (+-)-Isomer,Methoxyhydroxyphenylglycol, (-)-Isomer,4 Hydroxy 3 methoxyphenylethylene Glycol,4 Hydroxy 3 methoxyphenylethyleneglycol,4 Hydroxy 3 methoxyphenylglycol
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006719 Homovanillic Acid A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid. 3-Methoxy-4-Hydroxyphenylacetic Acid,4-Hydroxy-3-Methoxyphenylacetic Acid,3 Methoxy 4 Hydroxyphenylacetic Acid,4 Hydroxy 3 Methoxyphenylacetic Acid,Acid, 3-Methoxy-4-Hydroxyphenylacetic,Acid, 4-Hydroxy-3-Methoxyphenylacetic,Acid, Homovanillic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
August 1970, Nihon Naibunpi Gakkai zasshi,
J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
January 1970, Fiziolohichnyi zhurnal,
J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
February 1984, Annals of neurology,
J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
January 1992, Clinical neuropharmacology,
J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
January 1979, Vestnik Akademii meditsinskikh nauk SSSR,
J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
June 1968, Klinische Wochenschrift,
J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
November 1973, The Journal of cell biology,
J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
September 1973, Singapore medical journal,
J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
June 1999, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
J W Maas, and S A Contreras, and A L Miller, and N Berman, and C L Bowden, and M A Javors, and E Seleshi, and S E Weintraub
October 2009, European archives of psychiatry and clinical neuroscience,
Copied contents to your clipboard!